Encarnación-Rosado, Joel
Sohn, Albert S. W.
Biancur, Douglas E.
Lin, Elaine Y.
Osorio-Vasquez, Victoria http://orcid.org/0000-0001-7956-1633
Rodrick, Tori
González-Baerga, Diana
Zhao, Ende
Yokoyama, Yumi
Simeone, Diane M. http://orcid.org/0000-0001-5142-3087
Jones, Drew R. http://orcid.org/0000-0001-8732-9818
Parker, Seth J.
Wild, Robert
Kimmelman, Alec C. http://orcid.org/0009-0002-9465-8411
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA117969, P30CA016087, 1R01CA251726)
Lustgarten Foundation
Article History
Received: 7 July 2022
Accepted: 6 September 2023
First Online: 9 October 2023
Competing interests
: A.C.K. has financial interests in Vescor Therapeutics and is an inventor on patents pertaining to KRAS-regulated metabolic pathways and redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, targeting alanine transport, and the autophagic control of iron metabolism. A.C.K. is on the scientific advisory board of Rafael/Cornerstone Pharmaceuticals and OncoRev, and has been a consultant for Deciphera and Abbvie. R.W. and Y.Y. are employees and have an ownership interest in Dracen Pharmaceuticals. The other authors declare no competing interests.